S&P 500   3,104.77 (+0.04%)
DOW   27,815.08 (+0.18%)
QQQ   201.19 (-0.25%)
CGC   18.23 (-10.15%)
BABA   184.24 (-0.34%)
GE   11.63 (+0.87%)
T   37.81 (+0.56%)
ACB   2.76 (-11.84%)
F   8.85 (+1.49%)
BAC   33.15 (+0.91%)
S&P 500   3,104.77 (+0.04%)
DOW   27,815.08 (+0.18%)
QQQ   201.19 (-0.25%)
CGC   18.23 (-10.15%)
BABA   184.24 (-0.34%)
GE   11.63 (+0.87%)
T   37.81 (+0.56%)
ACB   2.76 (-11.84%)
F   8.85 (+1.49%)
BAC   33.15 (+0.91%)
S&P 500   3,104.77 (+0.04%)
DOW   27,815.08 (+0.18%)
QQQ   201.19 (-0.25%)
CGC   18.23 (-10.15%)
BABA   184.24 (-0.34%)
GE   11.63 (+0.87%)
T   37.81 (+0.56%)
ACB   2.76 (-11.84%)
F   8.85 (+1.49%)
BAC   33.15 (+0.91%)
S&P 500   3,104.77 (+0.04%)
DOW   27,815.08 (+0.18%)
QQQ   201.19 (-0.25%)
CGC   18.23 (-10.15%)
BABA   184.24 (-0.34%)
GE   11.63 (+0.87%)
T   37.81 (+0.56%)
ACB   2.76 (-11.84%)
F   8.85 (+1.49%)
BAC   33.15 (+0.91%)
Log in

United Therapeutics Stock Price, Forecast & Analysis (NASDAQ:UTHR)

$93.72
+0.32 (+0.34 %)
(As of 11/22/2019 10:56 AM ET)
Today's Range
$93.25
Now: $93.72
$94.46
50-Day Range
$78.30
MA: $85.85
$95.32
52-Week Range
$74.31
Now: $93.72
$128.94
Volume5,058 shs
Average Volume467,152 shs
Market Capitalization$4.11 billion
P/E Ratio7.00
Dividend YieldN/A
Beta0.97
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$14.53 per share
Book Value$61.89 per share

Profitability

Net Income$589.20 million

Miscellaneous

Employees860
Market Cap$4.11 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.


United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported $3.16 earnings per share for the quarter, topping analysts' consensus estimates of $2.34 by $0.82. The biotechnology company had revenue of $401.50 million for the quarter, compared to analyst estimates of $342.28 million. United Therapeutics had a negative net margin of 6.04% and a negative return on equity of 3.54%. United Therapeutics's quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $3.98 earnings per share. View United Therapeutics' Earnings History.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for United Therapeutics.

What price target have analysts set for UTHR?

9 equities research analysts have issued 1 year price targets for United Therapeutics' stock. Their forecasts range from $85.00 to $273.00. On average, they anticipate United Therapeutics' stock price to reach $124.11 in the next year. This suggests a possible upside of 32.2% from the stock's current price. View Analyst Price Targets for United Therapeutics.

What is the consensus analysts' recommendation for United Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for United Therapeutics.

Has United Therapeutics been receiving favorable news coverage?

Media stories about UTHR stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. United Therapeutics earned a news impact score of 1.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for United Therapeutics.

Who are some of United Therapeutics' key competitors?

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Celgene (CELG), Gilead Sciences (GILD), General Electric (GE), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Allergan (AGN), NVIDIA (NVDA), CytoDyn (CYDY), Skyworks Solutions (SWKS) and Johnson & Johnson (JNJ).

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the folowing people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 64)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 47)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 51)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Kevin T. Gray, Sr. VP of Strategic Operations & Logistics

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (1.83%), Greylin Investment Mangement Inc. (0.41%), Russell Investments Group Ltd. (0.36%), Sector Gamma AS (0.34%), Virginia Retirement Systems ET AL (0.33%) and California Public Employees Retirement System (0.26%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

Which institutional investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Denali Advisors LLC, Railway Pension Investments Ltd, Robeco Institutional Asset Management B.V., Russell Investments Group Ltd., Hussman Strategic Advisors Inc., Permanens Capital L.P. and Alps Advisors Inc.. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics.

Which institutional investors are buying United Therapeutics stock?

UTHR stock was acquired by a variety of institutional investors in the last quarter, including Sector Gamma AS, Tamarack Advisers LP, Virginia Retirement Systems ET AL, State of New Jersey Common Pension Fund D, Greylin Investment Mangement Inc., Mackay Shields LLC, California Public Employees Retirement System and Empirical Finance LLC. View Insider Buying and Selling for United Therapeutics.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $93.86.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $4.12 billion and generates $1.63 billion in revenue each year. The biotechnology company earns $589.20 million in net income (profit) each year or $13.39 on an earnings per share basis. United Therapeutics employs 860 workers across the globe.View Additional Information About United Therapeutics.

What is United Therapeutics' official website?

The official website for United Therapeutics is http://www.unither.com/.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]


MarketBeat Community Rating for United Therapeutics (NASDAQ UTHR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  439 (Vote Outperform)
Underperform Votes:  592 (Vote Underperform)
Total Votes:  1,031
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel